Dear customer, we would like to introduce our new products from July 2020 and hope you will find them interesting.
|RN0001100||Human||ACE2 (18-615)||100 µg||CHO cells|
|RN0001020||Human||ACE2 (18-615)||20 µg||CHO cells|
|RP1791127005||Human||ACE2 (18-740), Biotinylated||5 µg||HEK293|
|RP1791127050||Human||ACE2 (18-740), Biotinylated||50 µg||HEK293|
|RN0002100||Human||ACE2 (19-740)||100 µg||CHO cells|
|RN0002020||Human||ACE2 (19-740)||20 µg||CHO cells|
|RD172592100||Human||CTGF N-terminus||0.1 mg||E. coli|
|RD172124025||Human||ENPP1 Protein||0.025 mg||HEK293|
|RD275597100||Mouse||ENPP1 Protein||0.1 mg||HEK293|
|RD172575100||Human||Fibroblast growth factor 7||0.1 mg||E. coli|
|RD172604100||Human||IGF-1 E3R||0.1 mg||E. coli|
|RD975598100||SARS||SARS-CoV-2 Nucleocapsid Protein (NP)||0.1 mg||HEK293|
|RN0005100||SARS||SARS-CoV-2 Spike Glycoprotein S1||100 µg||HEK293|
|RN0005500||SARS||SARS-CoV-2 Spike Glycoprotein S1||500 µg||HEK293|
|RN0012100||SARS||SARS-CoV-2 Spike Glycoprotein S1||100 µg||Insect Cells|
|RN0012500||SARS||SARS-CoV-2 Spike Glycoprotein S1||500 µg||Insect Cells|
|RN0006100||SARS||SARS-CoV-2 Spike Glycoprotein S1 RBD||100 µg||HEK293|
|RN0006500||SARS||SARS-CoV-2 Spike Glycoprotein S1 RBD||500 µg||HEK293|
|RN0007020||SARS||SARS-CoV-2 Spike Glycoprotein S1 RBD||20 µg||CHO cells|
|RN0007100||SARS||SARS-CoV-2 Spike Glycoprotein S1 RBD||100 µg||CHO cells|
|RN0008020||SARS||SARS-CoV-2 Spike Glycoprotein S1 RBD, Fc||20 µg||CHO cells|
|RN0008100||SARS||SARS-CoV-2 Spike Glycoprotein S1 RBD, Fc||100 µg||CHO cells|
|RN0005100H||SARS||SARS-CoV-2 Spike Glycoprotein S1, HRP labelled||100 µg||HEK293|
|RN0004100||SARS||SARS-CoV-2 Spike Glycoprotein S2||100 µg||HEK293|
|RN0004500||SARS||SARS-CoV-2 Spike Glycoprotein S2||500 µg||HEK293|
|RN0009100||SARS||SARS-CoV-2 Spike Glycoprotein S2||100 µg||Insect Cells|
|RN0009500||SARS||SARS-CoV-2 Spike Glycoprotein S2||500 µg||Insect Cells|
|RN0011100||SARS||SARS-CoV-2 Spike Glycoprotein S2 (1000-1200)||100 µg||E. coli|
|RN0011500||SARS||SARS-CoV-2 Spike Glycoprotein S2 (1000-1200)||500 µg||E. coli|
|RN0010100||SARS||SARS-CoV-2 Spike Glycoprotein S2 (800-1000)||100 µg||E. coli|
|RN0010500||SARS||SARS-CoV-2 Spike Glycoprotein S2 (800-1000)||500 µg||E. coli|
|RN0004100H||SARS||SARS-CoV-2 Spike Glycoprotein S2, HRP labelled||100 µg||HEK293|
|RN0003100||SARS||SARS-CoV-2 Spike N-Terminal Domain NTD||100 µg||HEK293|
|RN0003500||SARS||SARS-CoV-2 Spike N-Terminal Domain NTD||500 µg||HEK293|
|RI975603100||SARS||SARS-CoV-2 Spike S1 protein||100 µg||HEK293|
HEK293-expressed SARS-CoV-2 Nucleocapsid Protein (NP) (RD975598100)
SARS-CoV-2 Spike Glycoprotein S1 RBD (RN0006100)
Nucleocapsid protein (NP) is the most abundant protein on the helical nucleocapsid of coronavirus, which envelopes the entire genomic RNA. The S1 subunit binds the cellular receptor through its receptor-binding domain (RBD), followed by conformational changes in the S2 subunit, which allows the fusion peptide to insert into the host target cell membrane.
The two proteins are frequently used as immobilized antigens in anti-COVID-19 antibody detection tests (ELISA, Immunochromatography rapid tests, etc).
Commonly used E.coli-produced antigens may contain traces of host (E.coli) proteins and interfere with anti-E.coli antibodies circulating in human sera. This represents an increased risk of obtaining non-specific results.
The HEK293-expressed proteins are free of host bacteria protein contamination and the risk of non-specific results is minimized.
See more about HEK293-expressed SARS-CoV-2 Nucleocapsid Protein (NP) (RD975598100) and SARS-CoV-2 Spike Glycoprotein S1 RBD (RN0006100)
NEW miREIA KITS
|CAT. NO.||NAME||ASSAY FORMAT|
|RDM0043B||blv-miR-B1-3p||miREIA – miRNA enzyme immunoassay|
Featured product: blv-miR-B1-3p miREIA
blv-miR-B1-3p is one of the miRNAs encoded by Bovine Leukemia Virus (BLV).
BLV is a deltaretrovirus closely related to the Human T cell leukemia virus-1 (HTLV-1) and is estimated to infect over 83% of dairy herds and over 40% of all dairy cows in the United States.
Retroviruses were not expected to encode miRNAs because of the potential problem of self-cleavage of their genomic RNAs. This assumption has recently been challenged by experiments showing that BLV encodes miRNAs from intragenomic Pol III promoters.
BLV miRNAs mediate the expression of genes involved in cell signaling, cancer, and immunity. BLV miRNAs are essential to induce B-cell tumors in an experimental model and to promote efficient viral replication in the natural host.
BLV only causes leukemia in a small proportion of animals, but BLV+ cattle exhibit reduced milk production and longevity that is distinct from lymphoma development. BLV negatively affects production by interfering with cattle immunity and increasing the risk of secondary infections.
See more about blv-miR-B1-3p miREIA
For this and more BioVendor miREIA kits, please visit www.biovendor.com/mirna.
ON-REQUEST miREIA Production
Can't find what you are looking for? Do you need a miREIA kit that is not in our portfolio yet? Or perhaps a customized assay?
Contact us at microRNA@biovendor.com
Scheduling of custom miREIA production is described here: ON-REQUEST miREIA Production
BioVendor Analytical Testing Service
YOU KNOW WHAT – WE KNOW HOW
Get certified sample analysis directly from the source with our BATS.
Combining the expertise and experience of 25 years in research, development and manufacturing of immunoassays, BioVendor provides analytical services for universities, clinical centres, pharmaceutical and biotechnological industries. An extensive range of analytical solutions enable us to provide you with a perfect service for your research or product development.
What we measure
- Small non-coding RNA (miRNA, piRNA)
- Diagnostic biomarkers (hormones, cytokines)
- Quantitative analysis of small non-coding RNA (miRNA, piRNA) by RT-qPCR or miRNA immunoassys
- Hormones and cytokines (ELISA)
- High-throughput multiplex analysis (Luminex)
GET IN TOUCHWebsite: www.biovendor.com/biovendor-analytical-testing-service
Phone: +420 549 124 185
Protein and miRNA Markers in Pulmonary Diseases | BioVendor Webinar #3
The COVID-19 pandemic brought attention to pulmonary diseases and associated laboratory diagnosis markers. Pneumonia and acute respiratory distress syndrome (ARDS) represented the most deadly conditions in COVID-19 patients leaving behind survivors suffering from lung fibrosis scares or other critical pulmonary complications. We are going to exploit a long history of pulmonary disease biomarkers development in BioVendor and share our knowledge with you.
Key points covered in this webinar:
- Protein markers in Pulmonary disease
- miRNA biomarkers in Pulmonary diseases
- The role of miRNAs in COVID-19 development and protection
- Please see the webinar here.
Protein and miRNA Markers in Pulmonary Diseases
BioVendor News Let's keep in touch!
Click to sign up for our newsletter to receive regular updates: NEWLETTER